
TRex Bio, the US clinical-stage immunology company built on regulatory T cell (Treg) biology, has set terms for a Nasdaq initial public offering of 8,333,334 shares priced at $14 to $16 each, under the proposed ticker TRXB.
At the $15 midpoint, TRex expects net proceeds of about $111.3 million, rising to $128.7 million if underwriters fully exercise an option to buy a further 1,250,000 shares, according to an amended S-1 filed with the SEC Monday.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze